astrazeneca glp 1 ADA: AZ's oral GLP-1 shows 'competitive efficacy' in phase 2 The Rise of the GLP-1s:

The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis

Differential targeting of GSH1 and GSH2 is achieved by multiple transcription initiation: implications for the compartmentation of glutathione biosynthesis in the Brassicaceae.

While these results are promising, further research in human studies is needed to confirm if these effects are consistent for everyone

Regulatory bodies approved GLP-1 receptor agonists are TRULICITY (dulaglutide), BYETTA/BYDUREON (exenatide), VICTOZA (liraglutide), OZEMPIC/WEGOVY/RYBELSUS, (Semaglutide), MOUNJARO/ZEPBOUND (tirzepatide) and others